XML 116 R94.htm IDEA: XBRL DOCUMENT v3.24.0.1
Collaborative Arrangements - Additional Information (Details)
1 Months Ended 12 Months Ended
Oct. 31, 2019
Dec. 31, 2023
USD ($)
Agreement
VUMERITY    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Percentage of net sales in royalty payment   15.00%
Maximum percentage of product supplies on net sales 100.00%  
License agreement | Janssen | 9 O-H Risperidone Palimate [Member]    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Patent royalty rate (as a percent)   1.50%
Know-how royalty rate resets (as a percent)   3.50%
Period after the date of the first commercial sale of the product for license expiration   15 years
License agreement | Janssen | 9 O-H Risperidone Palimate [Member] | Net sales of below $250.0 million    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Know-how royalty rate (as a percent)   3.50%
License agreement | Janssen | 9 O-H Risperidone Palimate [Member] | Net sales between $250.0 million and 500.0 million    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Know-how royalty rate (as a percent)   5.50%
License agreement | Janssen | 9 O-H Risperidone Palimate [Member] | Net sales greater than $500.0 million    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Know-how royalty rate (as a percent)   7.50%
License agreement | Janssen | 9 O-H Risperidone Palimate [Member] | Minimum | Net sales between $250.0 million and 500.0 million    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Aggregate worldwide net sales   $ 250,000,000
License agreement | Janssen | 9 O-H Risperidone Palimate [Member] | Minimum | Net sales greater than $500.0 million    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Aggregate worldwide net sales   500,000,000
License agreement | Janssen | 9 O-H Risperidone Palimate [Member] | Maximum | Net sales of below $250.0 million    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Aggregate worldwide net sales   250,000,000
License agreement | Janssen | 9 O-H Risperidone Palimate [Member] | Maximum | Net sales between $250.0 million and 500.0 million    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Aggregate worldwide net sales   $ 500,000,000
License agreement | Janssen | RISPERDAL CONSTA    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Royalty rate (as a percent)   2.50%
Period after the date of the first commercial sale of the product for license expiration   15 years
Number of license agreements | Agreement   2
Notice period required to be given before termination of agreement   30 days
Period for resolving default or breach after the receipt of notice for termination of agreement   90 days
Manufacturing and supply agreement | Janssen | RISPERDAL CONSTA    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Period after the date of the first commercial sale of the product for license expiration   60 days
Notice period required to be given before termination of agreement   6 months
Manufacturing and supply agreement | Janssen | RISPERDAL CONSTA | Minimum    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Royalty rate (as a percent)   7.50%
Royalty rate upon termination of manufacturing and supply agreement (as a percent)   2.50%
Manufacturing and supply agreement | Janssen | RISPERDAL CONSTA | Maximum    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Royalty rate upon termination of manufacturing and supply agreement (as a percent)   5.00%